Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | PNLIP | P16233 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684228 | 0.87 | PDE7A (0.46) | ESRRAPDE7APNLIPNR1H4F2 | |
| SCHEMBL4466049 | 0.85 | CA12 (0.42) | STAT3NR1H4CA12CA1CA2 | |
| SCHEMBL3434742 | 0.84 | ESRRA (0.45) | ESRRAPNLIPSTAT3CA12CA1 | |
| SCHEMBL28880742 | 0.81 | PNLIP (0.52) | ESRRAPDE7APNLIP | |
| SCHEMBL3510341 | 0.78 | EPHX2 (0.51) | ESRRAPDE7APNLIPNR1H4ALDH1A1 | |
| SCHEMBL4318630 | 0.76 | PDE7A (0.63) | PDE7APNLIPF2F10ALDH1A1 | |
| SCHEMBL5918245 | 0.76 | HPGD (0.54) | ESRRACA12CA1CA2CA9 | |
| SCHEMBL380152 | 0.76 | CA12 (0.57) | STAT3NR1H4CA12CA1CA2 | |
| SCHEMBL16492362 | 0.76 | PDE7A (0.49) | PDE7APNLIPALDH1A1FFAR1 | |
| SCHEMBL28880745 | 0.75 | PNLIP (0.46) | ESRRAPDE7APNLIPNR1H4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2010036917-A1 | PREVENTION AND TREATMENT OF CANCER WITH RAS GENE MUTATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036910-A1 | HEART PROTECTION BY ADMINISTERING AN AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | OHTA YOSHIKAZU (JP) | 2010-04-01 | — | — | WO | disclosed |
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7507740-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | ESRRA 759/4885PDE7A 4084/4885PNLIP 4838/4885 |
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | ESRRA 759/4885PDE7A 4084/4885PNLIP 4838/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | ESRRA 759/4885PDE7A 4084/4885PNLIP 4838/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | ESRRA 759/4885PDE7A 4084/4885PNLIP 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.